CA
MXCT icon

Clearstead Advisors’s MaxCyte MXCT Stock Holding History

Clearstead Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16 Buy
+13
New +$13 ﹤0.01% 3597
2025
Q4 		– Sell
-97
Closed -$154 – 3074
2025
Q3 		$154 Buy
+97
New +$169 ﹤0.01% 2889

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $128M AUM
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Clearstead Advisors's MXCT Position: Q2 2026 in Review

Clearstead Advisors opened a new position in MaxCyte (MXCT) in Q2 2026: 13 shares worth $16. The stake represents ﹤0.01% of the portfolio and ranks #3597 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in MXCT as recently as Q3 2025.

Clearstead Advisors first reported a position in MXCT in Q3 2025 and has held it in 2 quarters since. The position peaked at $154 in Q3 2025. 122 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Clearstead Advisors held 13 shares of MaxCyte worth $16 as of Q2 2026.
  • MaxCyte was a new Clearstead Advisors position in Q2 2026.
  • MaxCyte made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3597 holding.
  • Clearstead Advisors first reported a position in MaxCyte in Q3 2025 and has held it in 2 quarters since.
  • Clearstead Advisors's MaxCyte position peaked at $154 in Q3 2025.
  • 122 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.